Other reports suggest that the induction of CSC differentiation could represent a new therapeutic strategy against GBM [81–83], and that tumors enriched in differentiated cells (i.e. co-expressing aldehyde dehydrogenase 1A1 and GFAP but not nestin or Sox2) correlate with better patients' survival [84]. Here, ALDH1A1 is linked to glioblastoma.